Navigation Links
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
Date:8/12/2008

EMERYVILLE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that enrollment into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for the treatment of acute ischemic stroke has reached the level of patients necessary to conduct a planned interim analysis across the two studies. NTI is currently studying whether Viprinex is safe and effective for treating acute ischemic stroke when given within six hours of stroke onset.

"We are very pleased to have reached the enrollment criteria to conduct the planned interim analysis," stated Paul E. Freiman, president and chief executive officer of NTI. "Our independent Data Safety Monitoring Board (DSMB) will meet to review the efficacy data on an unblinded basis for the first time. In addition, the DSMB will evaluate the safety of Viprinex, as they've been doing since the start of the studies."

Results of the interim analysis are expected in January 2009. The interim analysis will be based on the first 500 treated patients in the current trials who have completed their 90 day assessment. If the treatment effect observed for the ancrod patients is not better than that observed for the placebo patients, then the trials will be halted for futility, indicating that they are unlikely to demonstrate the benefit required for approval. If the trials are allowed to continue, NTI will not have access to any unblinded patient data until the trials are completed. The primary endpoint of the trials is the modified Rankin Score, a measure of disability.

"We believe that data from 500 patients is sufficient for the DSMB to conduct a thorough assessment of futility, and have accordingly moved up the interim analysis from earlier plans to conduct it at 650 patients," stated Warren W. Wasiewski, M.D., vice president and chief medical officer. "This is a significant milestone for the program and we are all looking forward to learning the outcome of this review."

About Ischemic Stroke

Ischemic stroke is caused by blockage of a blood vessel in the brain due to a clot. The lack of blood flow, or ischemia, leads to cell death. According to the American Heart Association, 87% of the 700,000 annual strokes in the United States are ischemic. Stroke is the third leading cause of death in the United States, behind heart disease and cancer, and the leading cause of disability. The only FDA-approved drug for the treatment of acute ischemic stroke is Activase(R) (alteplase), which currently must be given within three hours of stroke onset.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the outcome of the interim analysis, obtaining approval for Viprinex, levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
2. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
3. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
4. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
7. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
8. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
9. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
10. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
11. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... MUMBAI , March 23, 2017 /PRNewswire/ ... Teil von Piramal Enterprises Limited, gibt die ... Leiter bekannt. PPS bietet seinen globalen Pharmazeutikkunden ... Needleman wird eine wichtige Rolle für das ... spielen. Als kaufmännischer Leiter wird Herr Needleman ...
(Date:3/23/2017)... 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or ... pharmaceutical company, is pleased to announce that its ... from the U.S. Food and Drug Administration (FDA) ... for tetrabenazine tablets in the 12.5 mg and ... a generic equivalent of the branded product Xenazine ...
(Date:3/23/2017)... 2017 The global dermatology devices ... billion by 2025, according to a new report by Grand ... a faster rate due to rising concern amongst people regarding ... of esthetic procedures used for treating hair - and skin-related ... considered as the highest revenue generators for the market. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits delivery trailblazer, ... app and centralized benefits dashboard solving one of the top frustrations in employee ... For the first time, employees can access up-to-date information and account balances for ...
(Date:3/23/2017)... ... 23, 2017 , ... Hakim Unique Group (HUG) just closed ... Healthcom Group (CHG). , The HUG investment is a landmark move, expanding ... CHG is a growing, internationally recognized healthcare management, technology, and services organization. It ...
(Date:3/23/2017)... Scottsdale, AZ (PRWEB) , ... March 23, 2017 , ... ... helping people around the world to manage stress and anxiety. , “Buzzies change ... Serin, neuropsychologist, inventor and co-founder of Buzzies. , Since its launch date in December ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... of a new solution that enables organizations to easily reprint customer invoices, bills, ... Reprint Server’ automates all of the steps needed to retrieve and print the ...
(Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
Breaking Medicine News(10 mins):